Celgene (CELG) Reports Phase III IMpassion130 Study Met Co-Primary Endpoint of Progression-Free Survival
Tweet Send to a Friend
Celgene Corporation (NASDAQ: CELG) today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
